Actemra® (tocilizumab) – New indication
September 13, 2018 - Genentech announced the FDA approval of the subcutaneous (SC) formulation of Actemra (tocilizumab), for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
Download PDF
